# SLC6A2

Source: https://onco.cc/targets/slc6a2/  
OnCo record `slc6a2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SLC6A2 (Sodium-dependent noradrenaline transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.

## Summary

Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signalling neurotransmitter in the autonomic sympathetic nervous system. Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis. Can also mediate sodium- and chloride-dependent transport of dopamine.

Open Targets scores its association with cancer at 0.53 (direct and indirect evidence; datatypes literature 0.23, genetic association 0.00, clinical 0.86).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: solute carrier family 6 member 2; Sodium-dependent noradrenaline transporter; NET1; NAT1; SLC6A5
- Tags: cancer-genes-wave
- Symbol: SLC6A2
- Class: other
- Biology: Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signalling neurotransmitter in the autonomic sympathetic nervous system. Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis. Can also mediate sodium- and chloride-dependent transport of dopamine. Location: Cell membrane; Cell projection, axon; Synapse, synaptosome (UniProt). Locus 16q12.2 (HGNC).
- Where found: Neuroendocrine tumours: Open Targets association 0.58 with neuroendocrine neoplasm (MONDO_0019496)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.93. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:11048: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11048
- UniProt P23975: https://www.uniprot.org/uniprotkb/P23975/entry
- NCBI Gene 6530: https://www.ncbi.nlm.nih.gov/gene/6530
- Ensembl ENSG00000103546: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103546

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)

---
JSON: https://onco.cc/api/v1/entities/slc6a2.json